journal article·2025-11

Tuning the polyethylene glycol-lipid anchor length of lipid nanoparticles to enhance brain-targeted siRNA delivery

Haiyang Tong, Zesen Ma, Dongsheng Li, Jin Yu, Qingjun Zhu, Huajian Shi, Yanmin Zheng, Li Zhou, Hongjun Li, Pei Lv, Jiaru Chu, Baoqing Li, Changlin Tian

Acta Biomaterialia· Volume 207
Publisher page

Abstract

The blood-brain barrier (BBB) remains a major challenge in the treatment of central nervous system (CNS) diseases. Lipid nanoparticles (LNPs) have emerged as promising carriers for small interfering RNA (siRNA) delivery to the brain. However, their ability to penetrate the BBB remains limited, with typically <1 % of the injected dose reaching the brain. Among various design strategies, PEGylation of lipids has been widely used to improve nanoparticle stability, prolong circulation time, and modulate tissue distribution. Notably, the length of the Polyethylene Glycol-lipid (PEG-lipid) anchor has been shown to significantly affect LNP pharmacokinetics and tissue distribution, particularly in hepatic and tumor tissues. However, its impact on brain-targeted delivery remains poorly understood. Here, we systematically investigated the impact of different PEG-lipid anchor lengths on the brain delivery performance of LNPs. Our results demonstrate that LNPs with longer PEG-lipid anchors exhibit enhanced BBB penetration, increased brain accumulation, and reduced hepatic uptake following intravenous administration. Further investigation using a BBB model revealed that LNPs with longer anchors exhibited enhanced exocytosis in brain endothelial cells, resulting in superior transcytosis and the highest BBB crossing efficiency. To validate these findings under pathophysiological conditions, we evaluated the formulations in an orthotopic GBM mouse model. Notably, LNPs with longer PEG-lipid anchors achieved the most effective siRNA-mediated knockdown in vivo. These findings identify PEG-lipid anchor length as a critical and tunable design parameter for brain-targeted siRNA delivery, offering new insights for optimizing LNP performance in CNS therapeutics. STATEMENT OF SIGNIFICANCE: 1. Tuning the Polyethylene Glycol (PEG)-lipid anchor length of Lipid Nanoparticles enhances the efficiency of brain-targeted siRNA delivery. 2. Longer PEG-lipid anchors enhance BBB penetration and brain accumulation. 3. Enhanced BBB transport by longer anchors is mediated through increased transcytosis. 4. Longer PEG-lipid anchors enable stronger gene silencing in glioblastoma models.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. Alexander · J. Clin. Oncol. · 2017 · 35 · 240210.1200/JCO.2017.73.0119 ↗
2. The global burden of neurological disorders: translating evidence into policy10.1016/S1474-4422(19)30411-9 ↗
3. Brain gene therapy with Trojan horse lipid nanoparticles10.1016/j.molmed.2023.02.004 ↗
4. Strategies for delivering therapeutics across the blood-brain barrier10.1038/s41573-021-00139-y ↗
5. mRNA-based therapeutics–developing a new class of drugs10.1038/nrd4278 ↗
6. Nucleic acid drug vectors for diagnosis and treatment of brain diseases10.1038/s41392-022-01298-z ↗
7. mRNA-based cancer therapeutics10.1038/s41568-023-00586-2 ↗
8. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy10.1002/adma.202303261 ↗
9. Engineered mRNA delivery systems for biomedical applications10.1002/adma.202308029 ↗
10. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system10.1093/nar/gkae368 ↗
11. Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment10.1002/adma.202000416 ↗
12. Lipid nanoparticles: versatile drug delivery vehicles for traversing the blood brain barrier to treat brain cancer10.1002/adfm.202404234 ↗
13. Small interfering RNA for Gliomas treatment: overcoming hurdles in delivery10.3389/fcell.2022.824299 ↗
14. Chemistry of lipid nanoparticles for RNA delivery10.1021/acs.accounts.1c00544 ↗
15. Functionalized nanomaterials capable of crossing the blood-brain barrier10.1021/acsnano.3c10674 ↗
16. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
17. Recent advances in lipid nanoparticles for delivery of mRNA10.3390/pharmaceutics14122682 ↗
18. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
19. Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement10.1021/acsnano.1c04996 ↗
20. Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
21. siRNA functionalized lipid nanoparticles (LNPs) in management of diseases10.3390/pharmaceutics14112520 ↗
22. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics10.1039/C8CS00805A ↗
23. Modern methods for delivery of drugs across the blood-brain barrier10.1016/j.addr.2011.11.010 ↗
24. Lipid nanoparticle-mediated drug delivery to the brain10.1016/j.addr.2023.114861 ↗
25. Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases10.1016/j.jconrel.2025.113641 ↗
26. Systemically intravenous siRNA delivery into brain with a targeting and efficient polypeptide carrier and its evaluation on anti-glioma efficacy10.1016/j.cclet.2024.110228 ↗
27. Predictive high-throughput platform for dual screening of mRNA lipid nanoparticle blood-brain barrier transfection and crossing10.1021/acs.nanolett.3c03509 ↗
28. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery10.3390/vaccines12101148 ↗
29. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism10.1016/j.omtm.2025.101436 ↗
30. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities10.1016/j.jconrel.2024.04.022 ↗
31. Endosomal escape: a bottleneck for LNP-mediated therapeutics10.1073/pnas.2307800120 ↗
32. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment
33. The role of lipid components in lipid nanoparticles for vaccines and gene therapy10.1016/j.addr.2022.114416 ↗
34. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production10.1016/j.ijpharm.2020.119792 ↗
35. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles10.1021/acsnano.0c10064 ↗
36. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes10.1016/j.ymthe.2005.09.014 ↗
37. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing10.1039/D1NA00712B ↗
38. Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment10.1016/j.omtm.2025.101457 ↗
39. From in vitro to in vivo: the dominant role of PEG-lipids in LNP performance10.1016/j.ejpb.2025.114726 ↗
40. Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines10.1016/j.jconrel.2025.01.071 ↗
41. PEGylated lipid screening, composition optimization, and structure-activity relationship determination for lipid nanoparticle-mediated mRNA delivery10.1039/D5NR00433K ↗
42. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles10.1038/mtna.2013.66 ↗
43. Effect of PEG pairing on the efficiency of cancer-targeting liposomes10.7150/thno.10732 ↗
44. PEG length effect of peptide-functional liposome for blood brain barrier (BBB) penetration and brain targeting10.1016/j.jconrel.2024.06.005 ↗
45. Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA10.1186/s12951-024-02812-x ↗
46. Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method10.3390/pharmaceutics15020597 ↗
47. Scalable synthesis of lipid nanoparticles for nucleic acid drug delivery using an isometric channel-size enlarging strategy10.1007/s12274-023-6031-1 ↗
48. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting10.2147/IJN.S188016 ↗
49. An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy10.1016/j.biomaterials.2022.121645 ↗
50. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection10.1126/sciadv.abb4429 ↗
51. Optimizing peptide-conjugated lipid nanoparticles for efficient siRNA delivery across the blood-brain barrier and treatment of glioblastoma multiforme10.1021/acschembio.5c00039 ↗
52. The biomolecular corona of lipid nanoparticles for gene therapy10.1021/acs.bioconjchem.0c00366 ↗
53. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
54. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA10.1016/j.jconrel.2016.05.059 ↗
55. PLK1 inhibition promotes apoptosis and DNA damage in glioma stem cells by regulating the nuclear translocation of YBX110.1038/s41420-023-01302-7 ↗
56. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice10.1002/stem.1081 ↗